Cytokinetics said it has suspended development of tirasemtiv after it failed to differentiate itself from placebo in a statistically significant manner. Source: BioSpace

Instead of targeting a molecule called CD19 on the surface of the cancer cells, the new therapy targets a molecule called CD22. Source: BioSpace

Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace

Peptidream has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets. Source: BioSpace

Data will be submitted to health authorities globally, including the FDA and EMA. Source: BioSpace

Researchers are making great headway against cancer, even though it's currently still the second-leading cause of death in the U.S. Source: BioSpace

This biotech has had a year where its stock had grown 20 percent and roller-coastered down 20 percent, several times. Source: BioSpace

Genentech announced that its Phase III HAVEN 3 study of Hemlibra in adults and adolescents with hemophilia A without inhibitors to factor VIII had positive results. Source: BioSpace

Dr. Adams to further advance promising pipeline, including breakthrough therapy, NiCord, in phase 3 development as a universal bone marrow transplant solution. Source: BioSpace

PellePharm is aiming to launch Phase III trials of the topical hedgehog inhibitor in early 2018. Source: BioSpace